Otsuka Of Japan Joins Other MNCs And Considers R&D Investment Deal With Korean Ministry
This article was originally published in PharmAsia News
Executive Summary
Japan's Otsuka Pharmaceutical is considering signing a memorandum of understating regarding a research and development investment deal with the Korean Ministry of Health, Welfare and Family Affairs, the Korean agency disclosed May 29. Currently, Novartis Korea is in the process of signing a MOU in investing $100 million in R&D with the ministry, and Korean subsidiaries of AstraZeneca and Pfizer have signed the MOUs. Besides Ostuka, Sanofi-Aventis is also considering a similar investment. Korea requires a minimum of $100 million in such R&D investment deals. (Click here for more - Japanese language
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.